Importance of asparagine-381 and arginine-487 for substrate recognition in CYP4Z1.


Journal

Biochemical pharmacology
ISSN: 1873-2968
Titre abrégé: Biochem Pharmacol
Pays: England
ID NLM: 0101032

Informations de publication

Date de publication:
04 2020
Historique:
received: 11 12 2019
accepted: 06 02 2020
pubmed: 12 2 2020
medline: 1 9 2020
entrez: 12 2 2020
Statut: ppublish

Résumé

The human cytochrome P450 enzyme CYP4Z1 remains an understudied enzyme despite its association with poor prognosis and overexpression in breast cancer. Hence, CYP4Z1 has previously been suggested as an anti-breast cancer target. In the present study we employed extended mutation analysis to increase our understanding of the substrate binding mode of this enzyme. In a combined in vitro and in silico approach we show for the first time that residue Arg487 plays an important role in substrate recognition and binding of CYP4Z1. Using a large array of recombinant CYP4Z1 mutants we show that, apart from Asn381, all other postulated binding residues only play an auxiliary role in substrate recognition and binding. Different substrate interaction motifs were identified via dynamic pharmacophores (dynophores) and their impact on catalytically competent substrate binding was classified. These new insights on the substrate recognition and binding mode represent an important step towards the rational design of CYP4Z1 prodrugs and guide further investigations into the so far poorly understood physiological role of CYP4Z1.

Identifiants

pubmed: 32044355
pii: S0006-2952(20)30071-X
doi: 10.1016/j.bcp.2020.113850
pii:
doi:

Substances chimiques

Asparagine 7006-34-0
Arginine 94ZLA3W45F
CYP4Z1 protein, human EC 1.14.14.1
Cytochrome P450 Family 4 EC 1.14.14.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

113850

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest The authors declare no conflict of interest.

Auteurs

Wei Du (W)

School of Pharmaceutical Science and Technology, Health Sciences Platform, Tianjin University, Tianjin 30072, China.

David Machalz (D)

Pharmaceutical and Medicinal Chemistry (Computer-Aided Drug Design), Institute of Pharmacy, Freie Universität Berlin, Germany.

Qi Yan (Q)

School of Pharmaceutical Science and Technology, Health Sciences Platform, Tianjin University, Tianjin 30072, China.

Erik J Sorensen (EJ)

School of Pharmaceutical Science and Technology, Health Sciences Platform, Tianjin University, Tianjin 30072, China; Department of Chemistry, Princeton University, Princeton, NJ 08544, USA.

Gerhard Wolber (G)

Pharmaceutical and Medicinal Chemistry (Computer-Aided Drug Design), Institute of Pharmacy, Freie Universität Berlin, Germany. Electronic address: gerhard.wolber@fu-berlin.de.

Matthias Bureik (M)

School of Pharmaceutical Science and Technology, Health Sciences Platform, Tianjin University, Tianjin 30072, China. Electronic address: matthias@tju.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH